Calliditas confirms that the OLE (Open Label Extension study) treatment response is consistent with the NefIgArd study regarding UPCR and eGFR, a positive outcome. Calliditas will present the study results at the upcoming ERA EDTA symposium in late May 2024. Several studies have demonstrated the ability to stabilise the key eGFR rate during active treatment. This study provides a clinical outcome when using Tarpeyo beyond the initial nine months.